

Table 2: Effects of evolocumab on apoB100, apoB48 and triglyceride metabolism in patients with type 2 diabetes.

	Before evolocumab <i>n</i> =13	On evolocumab <i>n</i> =13	P-value
ApoB100 metabolism			
VLDL ₁ production (mg/d)	790 ± 230	750 ± 230	0.61
VLDL ₁ pool (mg)	61 ± 36	53 ± 45	0.34
VLDL ₁ FCR (pools/d)	17 ± 8.6	20 ± 11	0.68
VLDL ₁ to VLDL ₂ transfer (mg/d)	530 ± 300	510 ± 210	0.64
VLDL ₂ direct production (mg/d)	270 ± 91	230 ± 96	0.11
VLDL ₂ pool (mg)	130 ± 47	93 ± 58	0.013
VLDL ₂ FCR (pools/d)	6.6 ± 3.3	9.5 ± 4.2	0.0034
VLDL ₂ to IDL transfer (mg/d)	650 ± 210	620 ± 270	0.84
IDL direct production (mg/d)	47 ± 67	39 ± 48	0.96
IDL pool (mg)	190 ± 50	130 ± 49	0.0034
IDL FCR (pools/d)	3.5 ± 1.3	5.4 ± 3.2	0.15
IDL to LDL transfer (mg/d)	450 ± 190	310 ± 140	0.027
LDL direct production (mg/d)	110 ± 23	110 ± 21	0.89
LDL pool (mg)	1500 ± 470	460 ± 270	<0.001
LDL FCR (pools/d)	0.32 ± 0.15	0.78 ± 0.34	<0.001
Triglyceride metabolism			
VLDL ₁ production (g/d)	34 ± 18	33 ± 13	0.91
VLDL ₁ pool (g)	1.8 ± 1	1.8 ± 1.5	0.95
VLDL ₁ FCR (pools/d)	38 ± 27	37 ± 23	1
VLDL ₂ total production (g/d)	8.8 ± 3.8	8.5 ± 2.7	0.68
VLDL ₂ direct production (g/d)	2.4 ± 0.83	2.1 ± 0.86	0.31
VLDL ₂ pool (g)	1.1 ± 0.43	0.75 ± 0.43	0.0017
VLDL ₂ FCR (pools/d)	10 ± 6.3	15 ± 8.7	0.013
ApoB48 metabolism			
Total production (mg/d)	570 ± 60	580 ± 75	0.31
Post-prandial CM prod (mg/d)	240 ± 50	230 ± 43	0.91
CM-apoB48 FCR (pools/d)	37 ± 24	46 ± 32	0.27
CM-TG production (g/d)	66.5 ± 0	66.5 ± 0	NA
CM-TG FCR (pools/d)	41 ± 27	54 ± 31	0.27

Data are shown as mean ± SD. P-values have been calculated using the Wilcoxon signed-rank test.